[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100651218":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":19,"locations":10,"responsibleParty":26,"collaborators":28,"id":31,"slug":32,"hasResults":33,"nctId":34,"briefTitle":35,"officialTitle":35,"acronym":10,"eligibilityCriteria":36,"healthyVolunteers":33,"sex":37,"minAge":38,"maxAge":10,"enrollmentInfo":39,"targetDuration":10,"studyType":42,"phases":10,"briefSummary":43,"conditions":44,"keywords":46,"overallStatus":51,"whyStopped":10,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":10},{"fullName":5,"class":6},"Mario Negri Institute for Pharmacological Research","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with ovarian carcinoma",null,"Patients with ovarian carcinoma resistant to platinum drugs and PARPi",[13],"Other: Platinum drugs and PARPi",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Platinum drugs and PARPi","Patients with ovarian carcinoma resistant to platinum drugs and PARPi undergoing paracentasis and\u002For surgical with left-over tumor material.",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":24,"email":25},"Giovanna Damia, MD","CONTACT","+30 02 39014234","4234","giovanna.damia@marionegri.it",{"type":27,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[29],{"name":30,"class":6},"Istituto Europeo di Oncologia","100651218","implementation-of-new-models-of-ovarian-carcinoma-resistant-to-therapy-100651218",false,"NCT07757711","Implementation of New Models of Ovarian Carcinoma Resistant to Therapy","Inclusion Criteria:\n\n* Female patients with malignant ovarian gynecological disease.\n* Age 18 years or older.\n* Patients capable of providing informed consent.\n\nExclusion Criteria:\n\n-Failure to sign the informed consent form.","FEMALE","18 Years",{"count":40,"type":41},50,"ESTIMATED","OBSERVATIONAL","The project focuses on developing new experimental models of ovarian cancer that accurately reflect patients who do not respond to first-line platinum-based treatments and who are resistant to PARP inhibitors (PARPi). These models are essential for testing new drugs or drug combinations in preclinical settings that closely mimic real clinical conditions. These models will also help to identify predictive biomarkers of treatment response and to better understand the biological mechanisms behind therapy resistance.",[45],"Ovarian Cancer",[47,48,49,50],"Ovarian cancer","Resistance","Platinum drug","Parp inhibitors","NOT_YET_RECRUITING","2026-08-05",{"date":54,"type":55},"2026-08-11","ACTUAL",{"date":57,"type":41},"2026-08-01",{"date":59,"type":41},"2036-08-31",{"name":5,"class":6}]